Uncategorized
When the coronavirus struck in mid-March, most research work was put on hold. However, virologists had to remain active in studying different viruses similar to SARS-COV-2, a virus that causes COVID-19. It also led to the closure of schools and daycares, meaning women had to take responsibility of nurturing their children since they perform most of the work needed to raise kids.
Pandemic worsens existing inequalities
For a long time now, women have been underrepresented in scientific productivity. According to recent statistics, underrepresentation has increased by over 31%. Furthermore, these numbers have constantly reduced since the pandemic struck. Gender disparities have not only been seen in the research labs but also the submission of research articles. The number of male authors in common preprint servers increased by 6.5% while that of female-only grew by 2.6%.
The relative drop in women’s productivity started before the pandemic, but it has drastically risen after the pandemic. The decline in productivity has been attributed to factors such as childcare that have accelerated due to the closure of learning institutions. Furthermore, being a single mother is also another factor that has stalled their productivity.
Besides, the division of labor at homes has not been equal. Surveys indicated that women were doing more of the house duties as compared to what their male counterparts were doing. Furthermore, women also took care of old and sick relatives, hence reducing their scientific research contribution. Female academics have also been doing a lot of teaching than male scholars, and the transition to online education has also affected their research productivity.
Gender disparities may bring some consequences for COVID-19 research
The gender gap is going to affect COVID-19 research. Several surveys have indicated that only one-third of women authors have participated in the coronavirus research. Besides, women may be relegated from senior author positions to less influential lower authorship posts. Similarly, female economists have also experienced a drop in productivity during the pandemic. Analysis has indicated that female economists are less likely to publish on COVID-19 related issues than their male counterparts.
It is, therefore, beneficial to include more women researchers, especially with the COVID-19 pandemic, as it affects men and women differently. Women should thus be engaged in shaping the research response to this pandemic. Other groups such as the Hispanics, Native Americans, and blacks who are underrepresented in the scientific research should also be included as they have been unequally affected by the pandemic.
Having all these groups in designing drugs, vaccine trials, and other COVID-19 researches will ensure a better and complete result. It could give more room to publish the findings and could also attract more funding. Therefore, it is necessary to provide equal opportunities to both genders to avoid gender disparities, especially during the pandemic. Experts say companies like Predictive Oncology (NASDAQ: POAI) may already be implementing in-house solutions to the problems that their female staff are facing during this time.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE) today announced the execution of a definitive agreement to merge with privately held Mullen Technologies, Inc., a Southern California-based electric vehicle company. According to the update, in the stock-for-stock reverse merger, Mullen’s shareholders will receive a majority of the outstanding stock in the post-merger company. “Our team at Mullen Technologies is very proud to take the next step in completing this acquisition of Net Element,” Mullen’s CEO and Founder David Michery stated in the news release. “Mullen is dedicated to the development of environmentally friendly, affordable technology that will bring energy solutions to consumer products and communities in the near future. This acquisition provides the resources that Mullen can utilize to execute on its business model to integrate state-of-the-art, clean-battery technology into personal and commercial vehicles, and eventually sustainable, reusable battery technology into everyday consumer products.”
To view the full press release, visit http://ibn.fm/24sI9
About Net Element
Net Element, Inc. operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S., the Company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017, it was recognized by South Florida Business Journal as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
LOS ANGELES, CA / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
“For the first time in ten years, we were unable to host our mid-year conference, which caused us to dream up the LD 500,” stated Chris Lahiji, President of LD Micro. “This will be our most ambitious event to date, expected to feature over 300 companies to more than 20,000 attendees. While the economy and financial world have been turned upside down, investor interest is as high as we have ever seen, and we will have something for everyone. Our “Zooming with LD” series has created some significant momentum that we plan to ride out till the big week.”
REGISTER HERE
The preliminary list of presenting companies:
|
Acer Therapeutics
|
|
|
Acme United Corp
|
|
|
ADDvantage Technologies Group, Inc.
|
|
|
Adial Pharmaceuticals Inc.
|
|
|
Advaxis
|
|
|
Aehr Test Systems
|
|
|
AIkido Pharma Inc.
|
|
|
AIM ImmunoTech Inc.
|
|
|
Air Industries Group
|
|
|
Akerna
|
|
|
Algernon Pharmaceuticals
|
|
|
Alimera Sciences
|
|
|
Allot
|
|
|
Alpine 4 Technologies
|
|
|
American Shared Hospital Services
|
|
|
Amesite
|
|
|
AnalytixInsight Inc.
|
|
|
Annovis Bio
|
|
|
Antibe Therapeutics
|
|
|
Apollo Endosurgery, Inc.
|
|
|
Applied Energetics, Inc.
|
|
|
Aptorum Group Limited
|
|
|
AquaBounty Technologies
|
|
|
Arch Therapeutics
|
|
|
Artelo Biosciences, Inc.
|
|
|
Assure Holdings
|
|
|
Asure Software
|
|
|
Atomera Incorporated
|
|
|
Atossa Genetics
|
|
|
Aurora Solar Technologies
|
|
|
AutoWeb, Inc.
|
|
|
Avivagen
|
|
|
AYRO Inc
|
|
|
Aytu BioScience Inc.
|
|
|
AzurRx BioPharma, Inc.
|
|
|
Ballard Power Systems Inc.
|
|
|
Bel Fuse, Inc.
|
|
|
BioCardia, Inc.
|
|
|
Biocept, Inc.
|
|
|
BioLargo, Inc.
|
|
|
Biomerica
|
|
|
BioSig Technologies
|
|
|
BioSyent Inc.
|
|
|
Blink Charging
|
|
|
BlueCity
|
|
|
Blueknight
|
|
|
BOQI International Medical Inc.
|
|
|
Bright Mountain Media
|
|
|
C-Bond Systems
|
|
|
Caladrius Biosciences, Inc.
|
|
|
Calyxt, Inc.
|
|
|
Camtek Ltd.
|
|
|
Can-Fite BioPharma, Ltd.
|
|
|
Capstone Turbine Corporation
|
|
|
CEL-SCI Corporation
|
|
|
Cemtrex, Inc.
|
|
|
Chicken Soup for the Soul Entertainment, Inc.
|
|
|
ChromaDex
|
|
|
Cinedigm
|
|
|
Citius Pharmaceuticals, Inc.
|
|
|
CLPS Incorporation
|
|
|
Conversion Labs
|
|
|
Crown EK
|
|
|
CynergisTek, Inc.
|
|
|
Data443 Risk Mitigation
|
|
|
Delcath Systems Inc.
|
|
|
Digirad Corporation
|
|
|
Digital Ally
|
|
|
Dolphin Entertainment Inc.
|
|
|
Driven
|
|
|
electroCore
|
|
|
Energous
|
|
|
Energy Focus, Inc.
|
|
|
Energy Fuels
|
|
|
Enthusiast Gaming
|
|
|
EnviroLeach Technologies Inc.
|
|
|
Envision Solar
|
|
|
Esports Entertainment Group
|
|
|
Evogene
|
|
|
Excellon Resources
|
|
|
Exro Technologies Inc.
|
|
|
Foresight Autonomous Holdings Ltd.
|
|
|
Fortress Biotech
|
|
|
GAN Limited
|
|
|
Genasys Inc.
|
|
|
Genprex, Inc.
|
|
|
Gigatronics
|
|
|
GOLO Mobile Inc.
|
|
|
Greenbox POS
|
|
|
Greenbrook TMS NeuroHealth Centers
|
|
|
GSI Technology
|
|
|
Helius Medical
|
|
|
Heritage Global, Inc.
|
|
|
Hoth Therapeutics, Inc
|
|
|
iCAD
|
|
|
iClick Interactive
|
|
|
Iconic Brands
|
|
|
iConsumer Corp
|
|
|
Ideal Power
|
|
|
IDEAYA Biosciences
|
|
|
IEC Electronics
|
|
|
IMAC Holdings
|
|
|
Immunovia AB
|
|
|
IMV Inc.
|
|
|
Indonesia Energy Corporation
|
|
|
InfuSystems
|
|
|
Inpixon
|
|
|
Intellicheck, Inc.
|
|
|
inTEST Corporation
|
|
|
Inuvo, Inc.
|
|
|
Issuer Direct Corporation
|
|
|
Jerash Holdings
|
|
|
Kandi Technologies
|
|
|
Kindred Biosciences
|
|
|
Lantern Pharma
|
|
|
Lexaria Bioscience Corp.
|
|
|
LifeVantage
|
|
|
LightPath Technologies
|
|
|
Lightwave Logic
|
|
|
Limbach Holdings, Inc.
|
|
|
Lineage Cell Therapeutics, Inc.
|
|
|
LiveXLive Media, Inc.
|
|
|
Lomiko Metals Inc.
|
|
|
Mace Security International, Inc.
|
|
|
Magal Security Systems Ltd.
|
|
|
Mako Mining
|
|
|
Mama Mancini’s
|
|
|
Manitex International Inc
|
|
|
Marrone Bio Innovations
|
|
|
Matinas
|
|
|
Medallion Financial Corp.
|
|
|
Medexus Pharmaceuticals Inc.
|
|
|
Meritage Hospitality
|
|
|
Milestone Scientific
|
|
|
Monaker Group
|
|
|
MTBC, Inc.
|
|
|
My Size Inc.
|
|
|
Myomo
|
|
|
NameSilo Technologies
|
|
|
Nanalysis Corp.
|
|
|
Nano Dimension
|
|
|
Nanotech Security Corp.
|
|
|
NanoViricides, Inc.
|
|
|
Nemaura Medical
|
|
|
NeoGenomics
|
|
|
Nephros, Inc.
|
|
|
NervGen Pharma Corp.
|
|
|
Neubase Therapeutics, Inc.
|
|
|
Nova Leap Health Corp.
|
|
|
Oblong Inc.
|
|
|
OncoSec Medical Incorporated
|
|
|
OneSoft Solutions Inc.
|
|
|
OneStopSystems
|
|
|
OpSens Inc.
|
|
|
Optex Systems Holdings
|
|
|
Orion Energy Systems
|
|
|
PAVmed Inc.
|
|
|
Paxmedica
|
|
|
Performant
|
|
|
Piedmont Lithium
|
|
|
POET Technologies Inc
|
|
|
Predictive Oncology Inc.
|
|
|
Profire Energy
|
|
|
Protech Home Medical Corp.
|
|
|
Quantum Computing Inc.
|
|
|
Quest Patent Research Corporation
|
|
|
Ra Medical Systems
|
|
|
RADA Electronic Industries Ltd
|
|
|
RadNet, Inc.
|
|
|
Rekor Systems, Inc
|
|
|
Remark Holdings
|
|
|
Renesola Power
|
|
|
Salarius Pharmaceuticals
|
|
|
Sangoma Technologies
|
|
|
SG Blocks Inc.
|
|
|
SharpSpring, Inc.
|
|
|
ShiftPixy Inc.
|
|
|
Slinger Bag
|
|
|
Smith-Midland Corporation
|
|
|
Sono-Tek
|
|
|
SRAX, Inc.
|
|
|
Staffing 360 Solutions, Inc.
|
|
|
Summit Wireless Technologies
|
|
|
Super League Gaming, Inc.
|
|
|
The Joint Chiropractic
|
|
|
Theralink Technologies
|
|
|
Thunderbird Entertainment
|
|
|
Timber Pharmaceuticals
|
|
|
Tinybeans
|
|
|
Titan Medical Inc.
|
|
|
Tiziana Life Sciences PLC
|
|
|
Tonix Pharmaceuticals
|
|
|
Torchlight Energy Resources, Inc.
|
|
|
Trxade Group
|
|
|
Turtle Beach Corporation
|
|
|
UGE International Ltd.
|
|
|
Unigold
|
|
|
Ur-Energy Inc.
|
|
|
US Gold Corp
|
|
|
Verb Technology
|
|
|
VerifyMe
|
|
|
Versus Systems Inc.
|
|
|
Vertex Energy
|
|
|
Village Farms
|
|
|
VIQ Solutions
|
|
|
VirTra, Inc.
|
|
|
Vision Marine Technologies, Inc.
|
|
|
VistaGen Therapeutics
|
|
|
Volition RX Ltd
|
|
|
Vox Royalty
|
|
|
Voyager Digital (Canada) Ltd
|
|
|
Vuzix Corporation
|
|
|
Wandisco
|
|
|
WeedMD
|
|
|
WELL Health Technologies
|
|
|
Weyland Tech
|
|
|
WidePoint Corporation
|
|
|
Xinyuan Real Estate
|
|
|
Xpel Inc
|
|
|
Yield10 Bioscience, Inc.
|
|
|
ZAGG Inc
|
|
|
Zedge, Inc.
|
|
|
Zoom Telephonics
|
|
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming “500” in September is the Company’s most ambitious project yet, and the first event that can be accessed by anyone. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is riding a wave that pushed its stock up 20% with no DRIO-related news. An article published to MarketWatch today titled, “UPDATE: Teladoc and Livongo Health to merge in deal valued at $18.5 billion,” covers a move amid a trend toward virtual healthcare that places DRIO, a provider of digital health solutions, in the right place at the right time. The article reads, “Teladoc Health Inc. (NYSE: TDOC) and Livongo Health Inc. (NASDAQ: LVGO) said Wednesday they have agreed to merge in a deal valued at $18.5 billion to create a company that can serve a spectrum of health needs, using virtual care. Under the terms of the deal, Livongo shareholders will receive 0.592x shares of Teladoc plus $11.33 in cash per share owned. Teladoc shareholders will own about 58% of the combined entity, while Livongo shareholders will own the remaining 42%. The combination ‘creates a global leader in consumer centered virtual care,’ the companies said in a joint statement. The new entity is expected to have pro forma revenue of about $1.3 billion for 2020, equal to pro forma growth of 85%.”
To view the full press release, visit http://ibn.fm/IB93S
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Synthetic biology is becoming an important tool in a wide range of applications. In the sector of drug discovery, there are many areas where synthetic biology has played a vital role in faster and accurate drug development at lower expenses. With an increased application of DNA sequencing, synthetic biology is becoming essential to biotech and pharma scientists.
Furthermore, the tool has empowered drug discovery scientists to clone and synthesize DNA fragments to develop new drugs. Through it, researchers have resorted to automated platforms for rapid DNA synthesis. This technology is being looked at to generate more vaccine candidates for the SARS-COV-2 Virus faster than the more usual way.
Application of Synthetic Biology
Synthetic biology mechanisms have gained pace in the drug discovery channel. The tool is helping scientists in several areas in preclinical and clinical research. A major use of synthetic biology is developing a cell-free system that allows scientists to analyze and activate biology machinery. It is done without the baffling number of variables introduced by a live cell system. Furthermore, advanced synthetic systems have brought new ways of manipulating body systems for a better understanding of biology and the discovery of new drugs.
Rapid and accurate synthesis of DNA has been of benefit to the drug discovery process. The process has been very important, especially where cost and time-sensitive needs had to be considered in generating DNA fragments and expression of vectors or variant libraries. The advancement in synthetic biology techniques can be used to boost natural polymerases that can produce dozens of DNA fragments overnight.
Besides, synthesized clones and variant libraries can be essential in discovery biology, epitope grading, protein, and antibody engineering. Recently, variant libraries produced by synthetic biology were used by some researchers in designing and assembling a series of nanobody sequences. By using synthetic biology, the outcome was three times faster than using manual benchtop cloning methods. Additionally, synthetic biology has also been paired with CRISPR methods to aid in gene therapy development and disease modeling.
Speedy Vaccine Development
The broad gains of synthetic biology in drug discovery can be demonstrated in the recent efforts to develop vaccines for COVID-19. Besides, the tool was also successfully used to develop vaccines for the H7N9 avian flu, which never turned into a pandemic. Modern automation has also been availed in time for the emergence of the SARS-COV-2 outbreak.
Scientists have also been able to take genome assemblies produced by SARS-COV-2 and have used the sequence to come up with genomic constructs for potential vaccines, and so far five potential vaccines have been identified. The timeframe for testing these vaccines has also been reduced, courtesy of synthetic biology.
With this type of speed via synthetic biology, researchers are even aiming to develop region-specific vaccines. Such localized vaccines will be more effective and will even respond to localized mutations. The approach can also be viable for vaccines using the RNA, live attenuated virus, DNA, or viral vectors.
Seeing ahead
New approaches in synthetic biology have made this technology more accurate, more affordable, and faster. These advances are bringing synthetic biology to the field of drug discovery, which was not achievable before. Scientists have already demonstrated that implementing an automated synthetic biology podium can accelerate discovery research and speed the development of new therapies, so we should expect a lot in this direction from firms like Genprex Inc. (NASDAQ: GNPX).
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The presence of SARS-COV-2 in cats and dogs has caught the attention of scientists. Many scientists have been researching whether the pets can transmit other pathogens, such as drug-resistant bacteria, to human beings.
Effects of multidrug-resistant organisms crossing from pets to humans
A puppy had exhibited some signs of the coronavirus in North Carolina after three people from the family that owned it had tested positive for the disease. There were concerns about whether the pup had contracted the disease or not. However, after testing samples, the results were negative, but other pets in the same household had tested positive for the virus. It was a great concern for the scientists to see if the pets could transmit the virus to one another or to human beings.
It is not only COVID-19 that scientists are worried about, but they have also been studying whether multidrug-resistant organisms are transferrable from pets to humans. Cases of humans being infected by pet food have been recorded in many instances. For instance, more than 150 people in different states were infected with a multidrug resistant salmonella. It occurred after they had handled a contaminated pig-ear pet treat. Pet food has also been a source of antibiotic-resistant bacteria, according to multiple pieces of research.
Some researchers have therefore resorted to testing raw dog food to establish whether it hosts some of these multidrug-resistant bacteria. The researchers realized that the dog food harbored the antibiotic-resistant Enterococcus faecium, and this bacteria has been responsible for causing a lot of infections worldwide. The diseases are due to humans sharing some antibiotic-resistant species of Enterococcus with dogs. However, the origin of transmission has not been found yet.
Are pets capable of infecting humans with multidrug-resistant bacteria?
Two researchers gathered samples of dog foods from various outlets to ascertain if these contained multidrug-resistant bacteria. Samples of 15 dry foods, 22 wets, and 9 raw frozen food were collected. The three types of food were swabbed in agar plates to culture any living bacteria in it. The plates were then treated with antibiotics, and all the samples in the frozen raw food tested positive for multidrug resistant enterococci.
Only one sample of wet food and none of the dry foods had traces of resistant antibiotics. However, it was expected that the amount of those bacteria in the raw foods would be more than those in dry foods since they are not sterilized. The research also showed that some of the raw foods’ bacterial strains had mobile elements that promote antibiotic resistance. Some of those resistant strains had also been identified in people with a bacterial infection.
However, from the analysis, the overall evidence is weak that a large number of antibiotic-resistant bacteria are transferred from pets to humans at levels that can make humans sick. In case the transmission from pets to humans happens, then instances of infections are very rare.
It would be interesting to know what progress biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) are making in finding lasting solutions to some of these superbugs threatening human health.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR) announced a corrected date for an upcoming webcast in which company officials will review financial results for the quarter ended June 30, 2020. According to the correction, Energy Fuels management will host a webcast at 11 a.m. ET on Aug. 5, to discuss the company’s second-quarter financial results. Interested parties may participate by dialing 1-888-664-6392 (toll free in the United States and Canada). In addition, slides for the webcast are available at http://nnw.fm/dxMyR.
A link to a recorded version of the proceedings will be available shortly after the webcast by calling 1-888-390-0541 (toll free in the U.S. and Canada) and entering the code 758012#. This recording will be available until Aug. 19, 2020.
To view the full press release, visit http://nnw.fm/4672a
About Energy Fuels Inc.
Energy Fuels is the leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers – the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill, the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
For as long as marijuana has been used recreationally, there have been anecdotal reports among the women who enjoy cannabis that it spices things up in the bedroom. Heck, there are even THC infused lubricants on the market that promise increased arousal and better orgasms, but do they really work? Or is it a placebo effect, where it seems to work because you want it to work, or is there any truth behind these claims?
A growing body of research indicates that there is indeed a correlation between cannabis and sex, even though the science behind it is still a little fuzzy. A recent study that was published last week in the Journal Science Medicine asked women who used cannabis about their sexual experiences, and the researchers found that more frequent cannabis use was associated with heightened arousal, stronger orgasms, and greater sexual satisfaction in general.
“Our results demonstrate that increasing frequency of cannabis use is associated with improved sexual function and is associated with increased satisfaction, orgasm and sexual desire,” says the study authors. The team of researchers asked 452 women about their cannabis use and asked them to fill out a Female Sexual Function Index (FSFI), which is a questionnaire designed to assess sexual function over the past four weeks. The questionnaire scored desire, arousal, lubrication, orgasm, satisfaction and pain.
“To our knowledge, this study is the first to use a validated questionnaire to assess the association between female sexual function and aspects of cannabis use including frequency, chemovar and indication.” A higher FSFI score usually denotes better sexual function while a lower score indicates sexual dysfunction and as the researchers analyzed the survey results, they determined that more frequent cannabis consumption was associated with lower rates of sexual dysfunction.
Respondents who had higher FSFI scores used cannabis more frequently, and they also had a higher specific FSFI subdomain score, indicating greater arousal and better orgasms. The study also found that frequent cannabis consumption led to low levels of sex-related pain. However, the researchers couldn’t determine which marijuana products worked best for sexual stimulation.
“Our study did not find an association between cannabis chemovar, (for example THC vs. CBD, reason for cannabis use) and female sexual function. Neither the method of consumption nor the type of cannabis consumed seemed to impact sexual function.
Analysts think that the results of this study may not have come as a surprise to companies like The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) who have always believed that scientists still have a long way to go before the full benefits of cannabis are documented.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused waters and CBD-infused products, is among 49 SmallCap, MicroCap and NanoCap public companies that will present to a global investor audience at the SNN Network Virtual Conference on August 3-6, 2020. A keynote presentation by world-renowned investor and bestseller author, Jim O’Shaughnessy, chairman and co-chief investment officer, portfolio manager of O’Shaughnessy Asset Management, will start the event. Interested parties may attend and participate in the SNN Network Virtual Conference by registering at http://cnw.fm/rbw7k.
To view the full press release, visit http://cnw.fm/pxv8I
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies. To purchase A88CBD(TM) products online, visit www.A88CBD.com. To learn more about The Alkaline Water Company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Sensors, artificial intelligence, and virtual reality are some of the advanced technologies that have changed the pharmaceutical sector, and many of these technologies will allow physicians to focus on what makes them good at treating patients. Digital health will also help doctors in performing some of the repetitive tasks that are always monotonous. However, with these six medical specialties, healthcare is poised to benefit greatly.
General Practice
Several doctors are choosing this specialty to make long term impacts on patients’ lives. Furthermore, general practice specialists boast a lot of trust from their patients. The GPs have also reduced the patient’s time moving from one doctor to the other. They can diagnose an illness, give therapy, and offer health advice. With the wearables that relay a patient’s information to doctors notifying them of vital signs, GPs will be able to provide treatment advice remotely. With smart algorithms in place, the GPs will act as gatekeepers to other specialists and advise on rare diseases.
Pediatrics
There is always limited time while examining the health status of a pregnant mother and a baby. Sensors that monitor a mother’s and a child’s crucial signs mean that in emergencies, giving care will not depend on the mother’s luck. For instance, other technologies such as CRISPR are also coming in to treat genetic conditions in kids. The cheap whole-genome sequencing could also help pediatricians to access more information to diagnose and treat children.
Ophthalmology
The specialty is about to bring tremendous benefits to patients. For example, bionic eyes and renal implants are there to reinstate sight for those who have lost it. Besides, CRISPR has also been used to successfully restore vision from an inherited form of blindness. Smartphones with connected sensors and apps that use the phone’s camera have also been used to diagnose eye conditions of recent.
Oncology
The specialty is paving the way for precision medicine and targeted treatment. Oncologists are even customizing therapies based on the patient’s tumor molecular makeup and genetic background. The process is even made faster by measuring blood biomarkers and cheap genome sequencing. Furthermore, some companies are also developing fluid biopsies capable of detecting all types of cancer from the early stages. These biopsies are capable of filtering tumor cells from blood samples, enabling doctors to analyze tumors earlier without performing expensive surgeries. This is the sector where companies like Predictive Oncology (NASDAQ: POAI) feature prominently.
Gastroenterology
Its focus is on the digestive system and its disorders. Focus is to see what is happening in your stomach and how you can be helped. This is now easier; courtesy of a pill cam and millions of people have benefited from this capsule endoscopy. Doctors can now see your esophagus, small bowel, and colon using the capsule to monitor and diagnose the gastrointestinal tract. It can be done without sedating the patient unlike what happens during invasive endoscopic processes. Furthermore, food scanners are also emerging, and they will be beneficial to those with dietary restrictions and food allergies.
Surgery
Surgery is going to be more informational, driven by artificial intelligence and robotics in the coming years. Digital health is offering an amazing collaboration between humans and technology. The cooperation will raise the level of precision and efficiency of surgeries higher, which you have never experienced before. With all these improvements, digital health is going to be great in the future.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit
- The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs
- TumorGenesis, which specializes in creating laboratory-grown cancer cells directed towards ovarian cancer research, recently announced its first sale of cancer cell culture media to US university
- The global cell culture media market set to grow to over $2.4 billion per annum by 2024
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has revealed that Richard Gabriel, President of POAI’s subsidiary TumorGenesis, presented at the upcoming Precision in Drug Discovery & Preclinical Virtual Summit on July 23, 2020 (http://ibn.fm/8N14a).
TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, announced earlier in June that the company had sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/yK35y). As one of the featured keynote speakers at the upcoming conference, Richard Gabriel is expected to elaborate on the company’s ongoing breakthroughs within the field of oncological research as well as its future growth ambitions.
The inaugural Precision in Drug Discovery & Preclinical Virtual Summit, hosted by Precision Evolution Global, will serve as a unique platform for members of the bio-pharmaceutical industry to network and collaborate in an effort towards furthering their discovery and scientific strategies. Featuring over 150 attendees spread across over 25 countries, the summit is set to showcase the recent progress and research trends within the pharma-biotech and academic space, including new compounds, drug design and synthesis methods in addition to the latest technological innovations within the field.
The virtual gathering will also feature a number of notable keynote addresses while simultaneously facilitating pre-scheduled meetings between potential collaborators and a host of reliable service providers, in an attempt to assist the summit’s attendees in procuring solutions to their most pressing research challenges in 2020 and beyond.
Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. The company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells to be used in assisting researchers and clinicians identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they feed into TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample, to enable the development of a patient-specific treatment plan (http://ibn.fm/6SRYp).
A recent study by MarketWatch has forecast that the global cell culture media market is expected to grow to a value of $2.36 billion by 2024, driven by an 8.4% compounded annual growth rate over the next 4 years (http://ibn.fm/L4ZVJ). TumorGenesis, which has thus far centered its focus on ovarian-specific formulations, has hopes of leveraging their current capabilities to expand the portfolio of tools and services the company can offer to cancer researchers. “We believe by helping researchers develop cells and tumors that more closely mimic cells and tumor found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” stated TumorGenesis President Richard Gabriel.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR), on Friday reported its financial results for the quarter ended June 30, 2020. In addition, the company announced that it will host a webcast at 11:00 am ET (9:00 am MT) on Wednesday, August 5, 2020 to review these results. Interested parties may join the webcast by dialing 1-888-664-6392 (toll free in the U.S. and Canada) or by visiting the following link: http://nnw.fm/qH0OR. “Energy Fuels continued to consolidate our position as the clear leader in U.S. uranium production in Q2-2020, and we made significant progress in diversifying into rare earth element production,” Mark S. Chalmers, Energy Fuels’ president and CEO, stated in the news release.
To view the full press release, visit http://nnw.fm/ChO3x
About Energy Fuels Inc.
Energy Fuels is the leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers – the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill, the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
- Mullen extends LOI with S3R3 Solutions to assemble electric vehicles, manufacture electric vehicle batteries in Washington
- Plan calls for 1.3 million square feet of assembly, manufacturing, R&D facilities
- NETE, Mullen merger will make Mullen a publicly traded company, provide access to capital
Mullen Technologies recently announced that it has extended its letter of intent for the acquisition of a 1.3-million-square-foot electric vehicle manufacturing facility. The progression of this acquisition bodes well for Net Element (NASDAQ: NETE), a company which operates a payments-as-a-service transactional and value-added services platform. NETE recently entered an agreement (subject to definitive agreement, fairness opinion, shareholder and board approval) to merge with Mullen Technologies Inc., a Southern California-based electric vehicle company and owner of the proposed plant, which is slated for construction just outside of Spokane.
The news broke with the announcement that Mullen had extended a letter of intent with S3R3 Solutions to assemble electric vehicles and manufacture electric vehicle batteries in the West Plains, WA, area (http://ibn.fm/zgqrX). The LOI outlines plans for 1.3 million square feet of assembly, manufacturing and research and development facilities.
“Mullen’s vision is to begin assembly of electric vehicles and development of its battery packs in an initial facility of 500,000 square feet and expand into an addition 800,000 square feet as its battery production expands,” the announcement stated. “The proposed site would be leased by Spokane International Airport to S3R3 who would finance and build the facility through the use of a revenue bond. Mullen anticipates meeting the requirements of the LOI by late 2020, which would allow the planning, financing, permitting and construction of the facility to initiate. Chair of the S3R3 Board and County Commissioner Al French stated ‘S3R3 Solutions has proven its ability to streamline projects. and we stand ready to deliver on the Mullen project to bring hundreds if not thousands of jobs to the Spokane region.’” S3R3 Solutions is the Public Development Authority managing development in the West Plains Airport Area of Spokane.
According to a recent “Journal of Business” article, Mullen CEO and founder David Michery says work on the facility, which could employ up to 4,000 people in the future, might start as early as September (http://ibn.fm/C8bVo). The company is currently focused on obtaining sufficient funding for the project.
As part of those efforts, the statement noted, “Mullen Technologies has agreed to merge with Net Element (NASDAQ: NETE), a publicly traded company. The reverse merger, if approved and consummated, will make Mullen a publicly traded company, which will provide access to capital per CEO of Mullen Technologies David Michery. Mullen has also recently announced the execution of a Letter of Intent with Axiom Financial for $135 million in funding to acquire an existing electric vehicle manufacturing plant and for the deposit required by the Letter of Intent with S3R3 Solutions.”
Net Element Inc. operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the U.S., NETE aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM).
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused waters and CBD-infused products, today announced that it will present at the SNN Network Virtual Investor Conference at 12:30 p.m. Eastern Time on Wednesday, August 5, 2020. According to the update, the company’s president and CEO, Ricky Wright, will host the presentation and answer questions from investors. Interested parties may register for the virtual event by visiting http://cnw.fm/gueqi.
To view the full press release, visit http://cnw.fm/TElhH
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies. To purchase A88CBD(TM) products online, visit www.A88CBD.com. To learn more about The Alkaline Water Company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a provider of digital-marketing and consumer data-management technology solutions, provides next-gen tools for consumers and brands to communicate and monetize data – a commodity considered “big” by today’s standards. SRAX’s commercial prospects look especially promising with its positioning in the rapidly growing “Big Data” sector, set to hit $229.4 billion in 2025 (http://nnw.fm/Y7DQV). A recent article discussing SRAX’s innovative offerings reads, “SRAX’s BIGtoken platform has sought to capitalize on the growing demand for big data analytics through its broad user base as well as its extensive range of functionalities. Towards the end of 2019, the platform introduced the BIGtoken Lightning Insights functionality – a revolutionary tool which allows SRAX’s customers to instantly activate research and surveys about virtually any topic and pose it to BIGtoken’s extensive user base. Companies can choose to address their queries to BIGtoken’s extremely wide and diverse user base or opt to target extremely niche demographic and socio-economic sectors through the product’s over 25,000 points of segmentation and receive actionable audience insights within a matter of mere hours (http://nnw.fm/uHjwh).”
To view the full article, visit: http://nnw.fm/htOd8
About SRAX
SRAX is a digital-marketing and consumer data-management technology company. SRAX’s technology unlocks data for brands in the CPG, investor relations, luxury and lifestyle verticals. Through its various platforms, SRAX is monetizing its data sets and growing multiple recurring revenue streams. BIGtoken is a consumer-managed data marketplace where people can own and earn from their data. The platform also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences. Sequire is a premier platform for investor intelligence and communication. Through Sequire, public companies can track their investors’ behaviors and trends, and use those insights to engage current and potential investors across marketing channels. For more information on SRAX and its verticals, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, on Thursday announced participation by its chairman and CEO, Rodney Varner, in a second-round live interview on the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show. A replay of the interview is available for viewing on the company’s website. In addition, Genprex today announced that it will present at the Proactive Investors One2One Virtual Event at 1:40 p.m. ET on August 4, 2020. Varner will deliver a company overview, provide updates on its product pipeline, including its lead drug candidate, GPX-001, and discuss the company’s preclinical diabetes gene therapy candidate that may have the potential to cure type 1 and type 2 diabetes. Interested parties may register for the event at http://ibn.fm/XsTbH.
To view the full press release, visit http://ibn.fm/hVHDT and http://ibn.fm/ltdRI
About Genprex, Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, on Thursday announced its appointment of Marc Thomas as its chief executive officer, as well as the company’s results for the second quarter ended June 30, 2020. Thomas will succeed David Norris, who has served as the CEO of Wrap Technologies since December 2018 will retain his position as a director following the transition. “During the second quarter of 2020, our team adapted to an unconventional operating environment, successfully increasing awareness of the BolaWrap, driving sales, and positioning Wrap for accelerated growth,” David Norris, director of Wrap Technologies and former chief executive officer, stated in the news release. “Financially, the quarter was highlighted by a substantial increase in our cash position to $35.4 million as we successfully closed a $12.4 million financing arrangement with a group of our existing investors and received an additional $9.2 million during Q2 from the exercise of warrants. Thanks to our team’s flexibility, we also achieved record revenues of $833,000, and we exited the quarter with a $1.5 million backlog, which indicates that our sales channel remained robust despite the complications caused by the coronavirus pandemic. Subsequent to the quarter’s end, we also strengthened our leadership team with the appointment of Marc Thomas as our CEO, whose expertise will be integral to the next phase of Wrap’s evolution.”
To view the full press release, visit http://nnw.fm/QSfkq and http://nnw.fm/TlZlG
About Wrap Technologies, Inc.
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the company, please visit www.WrapTechnologies.com. Examples of recent media coverage are available as links under the “Media” tab of the website.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://nnw.fm/WRTC
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has completed a private placement transaction resulting in aggregate gross proceeds of an estimated $28.6 million. After deducting placement agent fees and other offering expenses, capital from the transaction, along with existing balance sheet cash, will be used to fund DRIO’s long-term strategic operating plan. “We are pleased to have the confidence of our largest shareholder and several new highly regarded healthcare investors as we expand our commercial to manage existing and anticipated near-term agreements with health care payers,” said Dario CEO Erez Raphael, chief executive officer of Dario. “The adoption rate of digital therapeutics has been accelerated by the current pandemic. Dario’s efficacious, value-oriented solution is well-positioned to compete in this largely untapped U.S. market.”
To view the full press release, visit http://ibn.fm/utz7J
About DarioHealth Corp.
DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. For more information, visit the company’s website at www.DarioHealth.com
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
David Norris to Remain on the Board of Directors Subsequent to CEO Transition
TEMPE, AZ / July 30, 2020 / Wrap Technologies, Inc. (the “Company” or “Wrap”) (NASDAQ:WRTC), an innovator of modern policing solutions, today announced that its Board of Directors has appointed Marc Thomas as its new Chief Executive Officer, effective today. Thomas will succeed David Norris, who has served as the Company’s Chief Executive Officer since December 2018, and who will retain his position as a director following the transition.
“On behalf of the Board of Directors, I would like to thank David for the many contributions he has made since becoming CEO,” said Scot Cohen, Executive Chairman of Wrap Technologies. “Under David’s leadership, Wrap has grown from a nascent business concept into a company with an established brand, a proven product, and a robust and growing, global customer base.”
“It’s been a great privilege to lead Wrap through its startup phase, and I’m very proud of the work the entire team has accomplished to bring the idea of a new remote restraint device to life,” said David Norris, Director of Wrap Technologies. “With worldwide sales accelerating, the board of directors, the rest of the management team, and I came to the conclusion that it was an appropriate time in the company’s history to bring on a leader with a deep operational background to support the Company’s growth. As a fellow shareholder and staunch believer in the importance of Wrap’s mission, I’m very encouraged that we’ve found such a capable leader in Marc, whose background and track record speak for themselves when it comes to experience in related fields and successfully scaling businesses.”
“I’d also like to personally welcome Marc aboard,” Cohen continued. “Marc has a long history of successfully leading and growing organizations, and we’re confident that the expertise he has developed across a broad array of industries will be of great benefit to Wrap. We’re very excited to have him as part of the team.”
Marc Thomas is an experienced executive with a diverse background who has successfully led and advised teams in a variety of industries including financial markets, aerospace engineering and manufacturing, management consulting, government, and the armed services.
Incoming Chief Executive Officer Marc Thomas commented, “With the momentum Wrap has been building over the past year, it’s an incredibly exciting time to be joining the team. Wrap is working to close a critical gap that exists in policing, and by doing so, it will benefit not just law enforcement officers, but all of us. Today, the BolaWrap is more prominent than ever before, and more and more agencies are beginning to view it as a ‘must have’ rather than a ‘nice to have.’ I’m looking forward to leveraging my past experience to help effectively scale the business and accelerate the Company’s growth over the coming quarters and years.”
Thomas joins Wrap from Thorium Capital Ventures and Consulting where, during his 14 year tenure as president and CEO, he was responsible for private equity deal sourcing, valuing, acquiring, and operating small to medium sized manufacturing and services companies, as well as serving as an interim president, CEO, and board member of several portfolio manufacturing and asset management companies. While serving as a Chief Operating Officer in a private equity portfolio company, Marc worked “shoulder-to-shoulder” with various direct reports and staffers to develop SOPs / SOWs / and key metrics to design and implement a growth strategy resulting in annual increases of 27% and 189% in sales revenues and operating profit, respectively.
From 2001 to 2006, he held multiple leadership positions at General Electric Company including manager of the Corporate Initiatives Group, general manager of Rail, and chairman, president, and CEO of Aviation Materials. At GE Aviation Materials, Marc designed and successfully implemented a turnaround strategy that rapidly grew the business from $151 million to $246 million in sales revenue, and $9 million to $31 million in operating profit.
During his career, Thomas has also served as an engagement manager at McKinsey & Company, a legislative assistant to the Office of Senator Dirk Kempthorne, a special advisor to the Office of the Vice President at the White House, an adjunct associate professor to the School of Engineering & Applied Sciences at Columbia University, and an assistant professor to the Department of Systems Engineering at the United States Military Academy.
Prior to his work in the private sector, Thomas served as a Detachment Commander and Civil-Military & Psychological Operations Officer in the 5th Special Forces Group in the United States Army. He holds a JD in corporate and intellectual property law from the University of Texas School of Law in Austin, an MBA in international finance and management as well as an MS in industrial engineering and operations research from Columbia University, and a BS in civil and environment engineering from Stanford University.
About Wrap Technologies (NASDAQ:WRTC)
Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.wraptechnologies.com. Examples of recent media coverage are available as links under the “Media” tab of the website.
Trademark Information: BolaWrap and Wrap are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.
Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company’s overall business, total addressable market and expectations regarding future sales and expenses. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors included in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
WRAP TECHNOLOGIES CONTACT:
Paul M. Manley
VP – Investor Relations
612-834-1804
pmanley@wraptechnologies.com
The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) announced that its entire A88CBD(TM) product line, including topical and ingestible consumer offerings, will be available in 17 of CBD Emporium’s retail stores. WTER produces premium bottled alkaline water, flavor-infused waters, and CBD-infused products sold under the brand names Alkaline88(R), A88 Infused(TM) and A88CBD, respectively. “We’re excited about A88CBD’s partnership with CBD Emporium, which represents the largest order to date for our in-demand A88CBD products,” said WTER president and CEO Richard Wright. “Our online presence has been increasing, and we’re equally thrilled to be expanding our national presence with brick-and-mortar retailers like CBD Emporium. Emporium is a fast-growing retail chain with storefronts across the U.S. Given their ambitious expansion plans, we look forward to serving their growing customer base.”
To view the full press release, visit http://cnw.fm/aWdh1
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies. To purchase A88CBD(TM) products online, visit www.A88CBD.com. To learn more about The Alkaline Water Company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company, quotes POAI CEO Dr. Carl Schwartz, where he states, “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing. Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers.”
To view the full article, visit: http://ibn.fm/5VAH1
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Electric vehicles expected to account for over half of global passenger car sales by 2040
- Growth in electric vehicles expected to drive oil demand down by 13.7 million barrels per day
- Proposed manufacturing facility comprises 1.3 million square feet, creation of 55 jobs at startup with up to 863 jobs created by 2026
Net Element (NASDAQ: NETE), a global technology group that operates electronic payment services, is currently in the planning stages to open a new electric vehicle (“EV”) manufacturing facility in conjunction with privately-owned Mullen Technologies (“Mullen”) via a proposed merger. With demand for electric vehicles growing globally, oil demand is expected to plummet by 13.7 million barrels a day, according to recent research by Bloomberg (http://ibn.fm/LBVZx), positioning the new company favorably as a leader in the electric vehicle industry both in the U.S. and abroad.
According to the report, electric vehicles are expected to account for over half of global passenger car sales by 2040, in addition to completely dominating the bus market. Besides the growing passenger market, electric vehicles are also projected to make headway into other areas, comprising over half of light commercial vehicle sales, 31% of the medium commercial market, and almost a fifth of the heavy truck market.
The electric vehicle industry has made substantial headway in recent years, catalyzed by the falling prices of EV batteries in addition to policy support through fuel economy regulations and China’s new energy vehicle mandate. Showcasing its market dominance, China is expected to account for almost half (48%) of all passenger car sales in 2025.
Pending definitive agreement, fairness valuation, and stockholder and board approval, the reverse merger between NETE and Mullen will allow Mullen to take control of NETE and bypass the lengthy process of going public. Anticipated to occur in the third quarter, the merger is expected to give Mullen stakeholders a majority of the stock in the newly formed public company.
“We believe the timing of this merger is ideal for Mullen Technologies,” said Mullen CEO David Michery (http://ibn.fm/eMbwh). “It comes on the preparation of our launch of the Dragonfly K50, which will be available in (the second quarter) of 2021 and through our retail network in California and Arizona.”
Pending requisite approvals, the new company has plans to open an electric sports car manufacturing facility in West Plains, Missouri. The proposed 1.3 million square feet of assembly and manufacturing space is expected to create 55 jobs at startup with up to 863 jobs created by 2026. An additional 3,000 jobs are projected to be created for the research and development of lithium-ion batteries through Mullen’s subsidiary company, Mullen Energy.
Besides Mullen Energy, the company has several other subsidiaries that include a series of pre-owned auto dealerships in California and Arizona that operate under the Mullen Auto Sales banner, a digital auto marketplace called CarHub, and a financing company called Mullen Finance Corp. that offers vehicle leases and loans. Unrelated to the automotive business is another Mullen subsidiary called Smart 8 Energy that sources ventilators, COVID-19 antibody test kits, virus test kits and personal protective equipment.
Ranked on Deloitte’s Technology Fast 500(TM) list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, NETE credits its progression to organic growth in its North America Transactions Segment. Crediting most of its success to its Unified Payments brand, NETE focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Jerrick Media Holdings (OTCQB: JMDA), a technology company and the parent company of Vocal, today announced that Mark Standish formally assumed the duties and responsibilities of chairman of Jerrick’s Board of Directors, by its unanimous vote, at a recent meeting held following the Company’s 2020 Annual Meeting of Shareholders. Mark Patterson and Laurie Weisberg also officially began their tenure as independent board directors. With these three new appointments now in effect, Jerrick has already begun benefiting from the board’s network, collective experience and proven capacity to propel its revenue growth and align resources to successfully execute its strategic vision. “In addition to being my longtime mentor and friend, Mark Standish brings deep expertise in financial services, strategic growth, and organizational development acquired over the course of an impressive career,” Jerrick CEO Jeremy Frommer said in the news release. “Mark’s leadership only further bolsters our momentum as we head into August, the month we expect to uplist.”
To view the full press release, visit http://nnw.fm/lO32D
About Jerrick Media Holdings, Inc.
Jerrick is the parent company and creator of the Vocal platform. The company creates technology-based solutions to solve problems for the creative community. Through Vocal, Jerrick identifies and leverages opportunities within the digital platform and content monetization space. Since launching in 2016, Vocal has become home to over 650,000 content creators and brands of all shapes and sizes, attracting audiences across its network of wholly owned and operated communities. For more information, visit the company’s website at www.jerrick.media.
NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://nnw.fm/JMDA
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
iClick Interactive Asia Group (NASDAQ: ICLK) recently presented a keynote speech on data-driven marketing in China at the Product Marketing Alliance’s Product Marketing Festival in APAC. Held from July 29 to July 30, 2020, the event is the world’s first and only online festival dedicated to product marketing in the Asia Pacific region. “While there is tremendous potential in the Chinese digital advertising market for international brands to build market share, long-term success requires a customized strategy specifically adapted to China’s complex market and cultural landscape,” Frankie Ho, president of International Business at iClick, stated in the news release. “iClick is focused on helping brands gain a better and deeper understanding of China’s market and creating the best marketing strategies backed by real-time data and advanced algorithms.”
To view the full press release, visit http://nnw.fm/7NTnP
About iClick Interactive Asia Group Limited
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe.
For more information, please visit ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://nnw.fm/ICLK
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Is the quality of research being compromised during the COVID-19 crisis? It is a question that should be asked by those who are involved in research expeditions. Research studies are crucial in coming up with discoveries; hence a lot of work ethics is always regarded. However, some loopholes may erupt, leading to some questions regarding the quality of research.
Scrutinizing research exceptionalism
The COVID-19 pandemic has continued to erode the norms of scientific research. As nations observe the ongoing efforts to understand and defeat theSARS-Cov2-Virus, clinical and laboratory studies have been conducted at supersonic speeds. Data has been generated in volumes that are somehow hard to comprehend.
However, these are extraordinary days, but it is not an avenue for compromising scientific standards. When it comes to the accuracy of the science, emergencies always demand exceptions to high standards in quality. Does research exceptionalism only occur on the verge of a pandemic? It should be a question of concern to the research fraternity. Some scientists seem to think that research exceptionalism is universal regardless of any circumstance. The difference is that many funders, researchers, and policymakers believe that you can exempt those shortcomings from the normal standards.
Factors contributing to research exceptionalism
These three problematic theories always underpin research exceptionalism:
- Some evidence, even when flawed, is preferable than suggestions of expending greater resources on demanding studies whose benefits are seen later.
- The opinion that the main features of uncompromising research, such as placebo comparators or randomization differ with clinician’s care obligations
- The possibility that sponsors and researchers are generally free to exercise broad responsibility for the form and design of research.
To clarify on the first point, a researcher argued that a little bit of information is dangerous. Researchers also emphasized that if people perceive, based on poorly conducted studies, that treatment is effective for Covid-19, they may be shy to come forward for placebo trials that may rigorously evaluate that effectiveness. It is a big issue since it can slow down the process of determining if a treatment is efficient.
Researchers further add that a lot of treatment is effective in small preliminary reports. However, when subjected to rigorous testing, they turn out to be unsafe and ineffective. For research to be informative and maintain the social value that research should uphold, it needs to fulfill the following responsibilities:
- Analytical design
- Its importance
- Feasibility
- Analytical integrity
- Complete reporting of the trial promptly and consistently with pre-specified analyses
Clinical trials
Developing, testing, and manufacturing a therapeutic or preventive agent is always lengthy at normal times. However, it is also essential to follow the required process, even amid a pandemic, without compromising health standards. Health agencies should, therefore, prioritize research approaches that are testing multiple interventions.
However, the recent innovations have eased clinical trials where five treatments can be tested in one clinical trial. These will not only economize on time but also will bring out better clinical trials. Therefore, it should be noted that even in a crisis, the research process must not be compromised. Furthermore, a big lesson that should be learned is that rigorous research during the COVID-19 pandemic is feasible.
It would be enlightening to hear what established players in the biomedical field like Genprex Inc. (NASDAQ: GNPX) have to say regarding how to navigate the research pitfalls brought on by the ongoing pandemic.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- DarioHealth Corp. is a digital therapeutics innovator that supplies remote monitoring technology to caregivers and their patients
- The company’s Remote Patient Monitoring (“RPM”) technology reports patient data to care providers in the clinical setting and if necessary provides occasional “nudges” to patients to maintain their level of care
- DarioHealth began working in North America with two agreements announced in June, and in July began offering its solutions to the United Kingdom and Ireland thanks to a third agreement
- Such remote services have been increasingly in demand amid the ongoing global pandemic, regarded as a solution for minimizing the risk of exposure to viral infections and improving hospitals’ capacity to accept the most critical care needs
When the novel coronavirus began to create a surge of infections during the spring in the Northeastern states, some hospitals such as Mount Sinai in New York and Atrius Health in Boston turned to their “hospital at home” (“HaH”) programs to limit the risk of patient exposure to the virus and to keep hospital beds available for the most critically ill amid the growing health crisis (http://ibn.fm/aPjBk).
“We began thinking about how we could use hospital-at-home to meet the needs of our hospital system in our community. … Rather than focusing on specific diagnoses, our focus has been on specific services that we’re able to render at home — and whether those are the services that are keeping the patient in the hospital,” Mount Sinai’s HaH Director Al Siu stated in a Home Health Care News report (http://ibn.fm/aaO6O).
DarioHealth (NASDAQ: DRIO) is an innovator in the digital therapeutics field that supplies hospitals with the technology they need to ensure that their patients are receiving the necessary level of care even if they are being “roomed” at home under a remote monitoring regimen.
Healthcare providers have become familiar with an ever-evolving array of computerized equipment necessary to capture data from patients in a clinical or hospital setting, but HaH technology-based services are still developing as a field of care. Personal health digital therapeutics solutions that generate data remotely and make it available to care providers in the clinical setting offer the potential of providing early warnings of a medical concern that may arise between doctor visits, as well as potentially eliminating the need for costly hospital readmissions by allowing a condition to be dealt with before it reaches a critical phase.
DarioHealth’s Remote Patient Monitoring (“RPM”) digital therapeutics platform provides physicians with essential information and also delivers occasional “nudges” to patients when its automated programming recognizes a need (http://ibn.fm/5ndmX).
Devices that monitor chronic health conditions such as diabetes can function over multiple years, potentially reducing the frequency of medical visits and the demands on care providers’ time. Since such devices generally function automatically without requiring the patient to press any buttons or mess with device-pairing and data entry needs, the patient can generally function normally with a minimum of cumbersome behavior.
DarioHealth’s RPM platform combines the functions of the company’s existing resource with app technology for the service’s users and with the DarioEngage coaching platform that helps physicians and large provider groups ensure they are billing according to approved remote patient monitoring codes.
In June, the company announced it had signed its first two remote patient monitoring agreements in North America (http://ibn.fm/WoWBN), and on July 20 DarioHealth announced it is adding international service thanks to a strategic partnership with Williams Medical that makes the RPM platform available to healthcare professionals across the United Kingdom and Ireland (http://ibn.fm/ZeDHN).
For more information, visit the company’s website at www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- As the spread of the novel coronavirus unexpectedly reached pandemic proportions, Trxade Group stepped in to help patients and providers continue to access resources and PPE products through a virtual environment that is safe from contagion
- If telemedicine services maintain popularity with patients and insurance providers continue to be responsive to reimbursing telehealth claims, market analysts project a seven-fold increase for the industry by 2025
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, reported its financial results for the second quarter ended June 30, 2020. According to the report, revenues for the second quarter of 2020 increased 244% to a record $6.6 million, compared to revenue of $1.9 million in the same quarter last year. Second quarter revenue was up 199% when compared to revenues of $2.2 million in the first quarter of 2020.
The pharmaceutical services provider has garnered much attention in the first half of 2020. The company has been working to raise awareness of its supply chain trading platform that includes medical consultation and prescription drug solutions.
As the spread of the novel coronavirus unexpectedly reached pandemic proportions and triggered the need for infection-fighting policies, Trxade Group has developed measures to help patients and providers continue to access resources through a virtual environment that is safe from contagion. In addition, the company supplied multiple organizations with COVID-19 rapid test kits for employees and families, providing a diagnosis within 15 minutes at the point of care. Trxade Group experienced significant revenue increase in personal protective equipment (“PPE”) sales by the Company’s Integra Pharma segment in response to the COVID-19 pandemic.
During the COVID-19 crisis, telehealth services have rapidly expanded. Telehealth claims to private insurers have grown 4,347% year-over-year (http://nnw.fm/KdQP2). CVS Health saw 600% growth in telehealth and virtual visits through its MinuteClinics in the first quarter of 2020 (http://nnw.fm/iabaP), Blue Cross and Blue Shield of Tennessee saw 50 times more telehealth visits in May (http://nnw.fm/HoW3M) and Blue Cross of Idaho processed more than 90,500 telehealth claims between March and June, with telehealth now representing more than one-quarter of all claims (http://nnw.fm/z9xpo).
If telemedicine services maintain popularity with patients and insurance providers continue to be responsive to reimbursing telehealth claims, market analysts at McKinsey & Company forecast a $250 billion market (http://nnw.fm/zYUhR) while Frost & Sullivan projects a seven-fold increase by 2025 (http://nnw.fm/eEivE).
Other operational highlights of Trxade Group’s Q2 results included the company’s sustained efforts to expand its platform nationwide. Trxade recently added 325 new independent pharmacies to its platform, bringing the total registered pharmacy members to over 11,725.
The company also engaged international investor relations specialists MZ Group to expand its comprehensive strategic investor relations program across all key markets. Chairman and Chief Executive Officer Suren Ajjarapu stated: “As we move through the second half of 2020, we are better positioned than ever to execute upon our vision of continued growth of the platform, driven by new independent pharmacies, new suppliers and distributors.”
Headquartered in Tampa, Florida, Trxade Group, Inc. is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible.
Founded in 2010, Trxade Group operates via four synergistic platforms: (1) B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, the company’s virtual wholesale division; (3) Bonum Health which offers affordable telehealth services; and (4) the DelivMeds app, a nationwide mail order delivery distribution network for independent pharmacies.
For more information, visit the company’s website at www.TrxadeGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused waters and CBD-infused products, today announced that it will participating virtually in the ECRM Beverage Program on July 29 -30, 2020. “We have had tremendous success at the various ECRM programs that our teams participate in throughout the year,” Frank Chessman, executive director of National Sales for The Alkaline Water Company, stated in the news release. “This year the ECRM Beverage program is virtual, and our team is approaching the event with the same vigor. With a strong slate of meetings, we are engaging with targeted companies that have expressed a keen interest in our brands and can help drive category success year-round. ECRM’s unique format of Efficient Program Planning Sessions creates highly productive one-on-one meetings with pre-qualified, key decision makers across a variety of retailers representing drug stores, grocery chains, convenience stores, and big-box stores.”
To view the full press release, visit http://cnw.fm/dMJoP
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies. To purchase A88CBD(TM) products online, visit www.A88CBD.com. To learn more about The Alkaline Water Company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest uranium producer in the United States and the leading producer of vanadium, finds itself in an ideal position as the company prepares to enter the rare earth elements (“REE”) sector. Earlier this year, Energy Fuels announced its entry into REEs — a space with growing interest that was highlighted in a recent “Forbes” article, which reads, “[REEs are] an awfully hot topic right now for two reasons. First, they’re increasingly in demand for critical modern technologies, ranging from computer hard drives and cell phones, to new-tech applications such as batteries for ‘EVs’ and clean power storage, to critical defense items such as jet engines and lasers. Second, supply is currently dominated by China (for mining alone, for example, China has 80% market share). China has cut off supplies to countries before, and just last year threatened to do so again, in retaliation against the trade war with America” (http://nnw.fm/Ei1e1).
To view the full article, visit: http://nnw.fm/4wsdY
About Energy Fuels Inc.
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the United States, including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU; the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR. For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
July 29, 2020
Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands out, having shown positive results for the treatment of anxiety, depression, addiction, and eating and other disorders. A recent article discussing the company’s positioning reads, “Cybin is potentially poised to be the first company to develop psilocybin-based medicine designed to target major depressive disorders. Currently involved in structuring a clinical study that will be conducted through an academic partner in the Caribbean, Cybin has already filled a patent application for a diverse set of delivery mechanisms, identified synthetic psilocybin active pharmaceutical ingredients (‘API’) sources and obtained a contract with a synthetic psilocybin oral film manufacturer.”
To view the full article, visit http://nnw.fm/fJMJ3
About Cybin Corp.
Cybin is a mushroom life-sciences company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
